To validate that enhanced signals resulted from specific binding and not passive diffusion, we compared MT218 to non-targeted gadoteridol in SD tumors after treatment (Figure S3) confirming that increased enhancement was due to EDB-FN-specific binding of MT218. This evidence concerns the gene FN1 and Salla disease.